FR15C0048I2 - Anticorps antagonistes de il-17 - Google Patents

Anticorps antagonistes de il-17

Info

Publication number
FR15C0048I2
FR15C0048I2 FR15C0048C FR15C0048C FR15C0048I2 FR 15C0048 I2 FR15C0048 I2 FR 15C0048I2 FR 15C0048 C FR15C0048 C FR 15C0048C FR 15C0048 C FR15C0048 C FR 15C0048C FR 15C0048 I2 FR15C0048 I2 FR 15C0048I2
Authority
FR
France
Prior art keywords
antagonist antibodies
antagonist
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0048C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0048(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of FR15C0048I1 publication Critical patent/FR15C0048I1/fr
Application granted granted Critical
Publication of FR15C0048I2 publication Critical patent/FR15C0048I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR15C0048C 2004-08-05 2015-07-03 Anticorps antagonistes de il-17 Active FR15C0048I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound
PCT/EP2005/008470 WO2006013107A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Publications (2)

Publication Number Publication Date
FR15C0048I1 FR15C0048I1 (fr) 2015-08-28
FR15C0048I2 true FR15C0048I2 (fr) 2015-11-20

Family

ID=32982602

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0048C Active FR15C0048I2 (fr) 2004-08-05 2015-07-03 Anticorps antagonistes de il-17

Country Status (40)

Country Link
US (9) US7807155B2 (forum.php)
EP (5) EP2364729B3 (forum.php)
JP (1) JP4682200B2 (forum.php)
KR (2) KR100852523B1 (forum.php)
CN (1) CN101001645B (forum.php)
AR (1) AR050200A1 (forum.php)
AT (1) ATE517924T1 (forum.php)
AU (2) AU2005268857C1 (forum.php)
BE (1) BE2015C041I2 (forum.php)
BR (3) BR122018075556B1 (forum.php)
CA (1) CA2573586C (forum.php)
CY (6) CY1111963T1 (forum.php)
DK (4) DK2364729T6 (forum.php)
EC (1) ECSP077198A (forum.php)
ES (4) ES2677245T3 (forum.php)
FR (1) FR15C0048I2 (forum.php)
GB (1) GB0417487D0 (forum.php)
HK (1) HK1256639A1 (forum.php)
HR (3) HRP20110758T4 (forum.php)
HU (4) HUE038187T2 (forum.php)
IL (1) IL180717A (forum.php)
LT (3) LT2902039T (forum.php)
LU (2) LU92768I2 (forum.php)
MA (1) MA28982B1 (forum.php)
MX (1) MX2007001338A (forum.php)
MY (1) MY144925A (forum.php)
NL (1) NL300749I2 (forum.php)
NO (9) NO336279B1 (forum.php)
NZ (1) NZ552658A (forum.php)
PE (1) PE20060418A1 (forum.php)
PL (4) PL2902039T3 (forum.php)
PT (4) PT2366405E (forum.php)
RU (2) RU2426741C3 (forum.php)
SG (1) SG155186A1 (forum.php)
SI (4) SI2902039T1 (forum.php)
TN (1) TNSN07034A1 (forum.php)
TR (1) TR201808057T4 (forum.php)
TW (1) TWI359153B (forum.php)
WO (1) WO2006013107A1 (forum.php)
ZA (1) ZA200700242B (forum.php)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PT1933869E (pt) 2005-09-01 2009-12-24 Schering Corp Utilização de antagonistas de il-23 e il-para tratar a doença inflamatória ocular auto-imune
DK2481753T3 (en) * 2005-12-13 2018-06-18 Lilly Co Eli Anti-IL-17 antibodies
PL2532681T3 (pl) 2005-12-20 2015-03-31 Sbi Biotech Co Ltd Przeciwciało anty-ILT7
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
EP1984401A2 (en) * 2006-01-31 2008-10-29 Novartis AG Il-17 antagonistic antibodies fpr treating cancer
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CN101646690B (zh) * 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
NZ579297A (en) 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
JP2010528086A (ja) 2007-05-29 2010-08-19 ノバルティス アーゲー 抗ｉｌ−１治療に関する新しい適応症
EP2171449A2 (en) * 2007-06-20 2010-04-07 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
KR101616995B1 (ko) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 슬리밍용 조성물
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP5886523B2 (ja) 2008-01-09 2016-03-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
UA102097C2 (ru) * 2008-04-29 2013-06-10 Амген Рисерч (Мюнхен) ГмбХ Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
WO2009136286A2 (en) 2008-05-05 2009-11-12 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
KR20110016958A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AU2009296299A1 (en) * 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human IL 17 and uses thereof
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
BRPI1014522B8 (pt) * 2009-04-27 2021-05-25 Novartis Ag anticorpo anti-actriib ou fragmento funcional, processo de produção dos mesmos, composição farmacêutica e usos
EP2427203B1 (en) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CA2777222A1 (en) * 2009-10-10 2011-04-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
CN102666875A (zh) 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5922025B2 (ja) 2009-10-30 2016-05-25 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−１７ａ拮抗物質
BR112012029588A2 (pt) 2010-05-20 2017-07-25 Ablynx Nv materiais biológicas relacionados a her3.
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2011285922B2 (en) * 2010-08-05 2016-06-16 Anaptysbio, Inc. Antibodies directed against IL-17
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
TWI564022B (zh) 2010-10-08 2017-01-01 諾華公司 利用ｉｌ-１７拮抗劑治療牛皮癬的方法
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
TWI618543B (zh) 2010-11-05 2018-03-21 諾華公司 Ｉｌ-１７抗體用於製備治療強直性脊椎炎之藥物之用途
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
RS56298B1 (sr) 2011-01-14 2017-12-29 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
CA2831787A1 (en) * 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
JP2015504430A (ja) * 2011-11-21 2015-02-12 ノバルティス アーゲー Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
WO2013116682A1 (en) 2012-02-02 2013-08-08 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013151670A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of nuclear proteins
JP6007310B2 (ja) 2012-04-05 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒトｔｗｅａｋ及びヒトｉｌ１７に対する二重特異性抗体並びにその使用
MX2014012640A (es) 2012-04-20 2015-01-15 Novartis Ag Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17.
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
US10434172B2 (en) * 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
HUE052184T2 (hu) 2013-11-18 2021-12-28 Shanghai hengrui pharmaceutical co ltd IL-17A kötõanyag és felhasználásai
EP3101035B1 (en) * 2014-01-28 2021-10-06 Beijing Hanmi Pharmaceutical Co., Ltd. Bifunctional fusion protein, preparation method therefor, and use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
SMT202400285T1 (it) 2014-09-10 2024-09-16 Novartis Ag Uso di antagonisti di il-17 per inibire la progressione del danno strutturale in pazienti affetti da artrite psoriasica
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
US10934335B2 (en) 2015-01-12 2021-03-02 Affibody Ab IL-17A-binding polypeptides
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016294332A1 (en) 2015-07-16 2017-11-30 Eli Lilly And Company Treatment of pruritus
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
AU2016342578A1 (en) 2015-10-19 2018-03-29 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (IL-17) antagonists
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
BR112018067951A2 (pt) 2016-03-10 2019-02-05 Viela Bio Inc moléculas que se ligam a ilt7 e métodos de uso destas
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
ES2992409T3 (es) 2016-07-19 2024-12-12 Novartis Ag Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
JP6802381B2 (ja) 2016-09-14 2020-12-16 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｉｌ−１７ａに特異的に結合する可能な抗体及びその機能的断片
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CA3080665A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17) antagonists
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
AU2018375738A1 (en) 2017-11-30 2020-06-11 Novartis Ag BCMA-targeting chimeric antigen receptor, and uses thereof
CN112203685A (zh) * 2018-03-29 2021-01-08 瑞美德生物医药科技有限公司 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
MY199538A (en) 2018-06-01 2023-11-06 Novartis Ag Binding molecules against bcma and uses thereof
US12134644B2 (en) 2018-07-31 2024-11-05 Weiqun SHEN Anti-IL-17A antibodies and use thereof
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN120025437A (zh) 2019-01-31 2025-05-23 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
WO2020243504A1 (en) * 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CN114286827B (zh) 2019-07-26 2024-01-12 神州细胞工程有限公司 人源化抗il17a抗体及其应用
WO2021018191A1 (zh) 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
KR20220066318A (ko) 2019-09-20 2022-05-24 노파르티스 아게 인터류킨-17(il-17) 길항제를 사용한 자가면역 질환의 치료 방법
TWI870471B (zh) * 2019-09-25 2025-01-21 國立大學法人東京大學 全身性硬化症治療用醫藥組合物
CN114729943B (zh) 2019-09-30 2025-07-22 詹森药业有限公司 用大分子调节剂进行il-17靶接合测定的组合物和方法
CN114728060A (zh) 2019-11-19 2022-07-08 诺华股份有限公司 使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法
CA3162052A1 (en) 2019-12-06 2021-06-10 Novartis Ag Methods of treating lichen planus using interleukin-17 (il-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
US20230235041A1 (en) 2020-06-23 2023-07-27 Novartis Ag Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022117773A1 (en) 2020-12-02 2022-06-09 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
JP2023554489A (ja) 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
KR20250005308A (ko) 2022-04-25 2025-01-09 노파르티스 아게 Il-17 억제제의 결정질 형태
IL317086A (en) 2022-05-16 2025-01-01 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
JP2025516723A (ja) 2022-05-18 2025-05-30 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
WO2024156841A1 (en) * 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) * 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
KR100467998B1 (ko) * 1995-03-23 2005-11-25 임뮤넥스 코포레이션 Il-17수용체
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DK0839196T3 (da) * 1995-07-19 2005-09-12 Inst Genetics Llc Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
EP0862454B1 (en) 1995-10-27 2002-08-28 Schering Corporation Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8 for treating infections
WO1998023284A1 (en) 1996-11-27 1998-06-04 Immunex Corporation Method of regulating nitric oxide production
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
JP4620243B2 (ja) 1997-11-10 2011-01-26 サイティミューン サイエンシーズ， インコーポレイテッド 生物学的に活性な因子の標的化された送達のための組成物および方法
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
EP1045905A2 (en) 1998-01-09 2000-10-25 Immunex Corporation Il-17rh dna and polypeptides
JP2002503478A (ja) 1998-02-11 2002-02-05 マキシジェン， インコーポレイテッド 遺伝子ワクチンベクターの標的化
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
EP1114156B1 (en) 1998-09-17 2007-11-14 ZymoGenetics, Inc. Mammalian transforming growth factor beta - 9 (ztgfss9)
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
JP2002534122A (ja) 1999-01-11 2002-10-15 シェーリング コーポレイション インターロイキン−１７関連哺乳動物サイトカイン、それをコードするポリヌクレオチド、使用
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
CA2360106C (en) 1999-02-12 2012-10-30 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ES2277947T3 (es) 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
DE60239450D1 (de) 2001-01-25 2011-04-28 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DK1391464T3 (da) * 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
WO2004019866A2 (en) 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
EP1633785B1 (en) * 2003-05-21 2012-11-28 Medarex, Inc. Human monoclonal antibodies against bacillusanthracis protective antigen
US20070269428A1 (en) 2003-11-21 2007-11-22 Celltech R&D Limited Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
CA2565566A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
PT1933869E (pt) * 2005-09-01 2009-12-24 Schering Corp Utilização de antagonistas de il-23 e il-para tratar a doença inflamatória ocular auto-imune

Also Published As

Publication number Publication date
ES2487533T3 (es) 2014-08-21
PL1776142T6 (pl) 2016-06-30
TNSN07034A1 (en) 2008-06-02
HRP20150480T1 (hr) 2015-07-17
SI1776142T1 (sl) 2011-11-30
PL2364729T6 (pl) 2016-06-30
HRP20110758T4 (hr) 2015-07-31
AU2005268857C1 (en) 2012-01-19
NO337129B1 (no) 2016-01-25
LU92768I2 (fr) 2015-11-03
US20140079719A1 (en) 2014-03-20
TW200617025A (en) 2006-06-01
KR20080029018A (ko) 2008-04-02
ES2487533T7 (es) 2015-07-14
US20090280131A1 (en) 2009-11-12
US10344084B2 (en) 2019-07-09
NO20150064L (no) 2007-03-30
LT2902039T (lt) 2018-06-25
BRPI0513078A (pt) 2008-04-22
AU2005268857A1 (en) 2006-02-09
ES2677245T3 (es) 2018-07-31
CY1120723T1 (el) 2019-12-11
US20150152178A1 (en) 2015-06-04
HUS1800040I1 (hu) 2018-11-28
EP2364729A2 (en) 2011-09-14
HUE025815T2 (en) 2016-04-28
US8617552B2 (en) 2013-12-31
RU2426741C3 (ru) 2017-11-15
ECSP077198A (es) 2007-02-28
EP2902039A1 (en) 2015-08-05
PT2364729E (pt) 2014-09-01
RU2011113153A (ru) 2012-10-20
DK1776142T6 (en) 2015-07-06
PL1776142T3 (pl) 2011-12-30
EP2366405B1 (en) 2015-02-25
CY1115444T1 (el) 2017-01-04
US20250122277A1 (en) 2025-04-17
NZ552658A (en) 2009-11-27
PL2366405T3 (pl) 2015-08-31
KR20070036166A (ko) 2007-04-02
HK1207559A1 (en) 2016-02-05
AU2010201689A1 (en) 2010-05-20
CY2015030I1 (el) 2015-11-04
HRP20181069T1 (hr) 2018-09-07
KR100852523B9 (ko) 2025-03-28
US20100215666A1 (en) 2010-08-26
EP3409288A1 (en) 2018-12-05
ES2367440T3 (es) 2011-11-03
JP4682200B2 (ja) 2011-05-11
ES2367440T7 (es) 2015-07-14
CY2015030I2 (el) 2017-11-14
IL180717A (en) 2012-07-31
PL2364729T3 (pl) 2014-10-31
US7807155B2 (en) 2010-10-05
BRPI0513078C1 (pt) 2021-05-25
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
TR201808057T4 (tr) 2018-06-21
BR122017009404B1 (pt) 2022-02-22
US20120107325A1 (en) 2012-05-03
ES2536228T3 (es) 2015-05-21
EP2366405A2 (en) 2011-09-21
LUC00088I2 (forum.php) 2018-12-17
EP2364729A3 (en) 2012-01-18
NO336279B1 (no) 2015-07-06
LTPA2015029I1 (lt) 2022-07-11
GB0417487D0 (en) 2004-09-08
US20170355762A1 (en) 2017-12-14
HUS1500037I1 (hu) 2017-10-30
US20190270804A1 (en) 2019-09-05
FR15C0048I1 (fr) 2015-08-28
NO20171697A1 (no) 2007-03-30
NO2016017I1 (no) 2016-08-23
LTPA2018515I1 (lt) 2018-10-25
SI2902039T1 (en) 2018-07-31
SG155186A1 (en) 2009-09-30
PL2902039T3 (pl) 2018-09-28
KR100852523B1 (ko) 2008-08-14
ZA200700242B (en) 2008-08-27
CY2018027I1 (el) 2020-05-29
EP1776142B3 (en) 2015-06-24
BRPI0513078B1 (pt) 2019-02-19
EP2902039B1 (en) 2018-04-11
NO20070985L (no) 2007-03-30
BE2015C041I2 (forum.php) 2024-10-08
NO348010B1 (no) 2024-06-17
ATE517924T1 (de) 2011-08-15
HK1256639A1 (en) 2019-09-27
CY2018027I2 (el) 2020-05-29
DK2366405T3 (en) 2015-05-11
BRPI0513078B8 (pt) 2019-08-27
NL300749I2 (nl) 2017-11-02
CY1116256T1 (el) 2017-02-08
MA28982B1 (fr) 2007-11-01
HK1101277A1 (en) 2007-10-12
NO2015023I2 (no) 2015-10-26
EP2364729B3 (en) 2015-06-24
CA2573586C (en) 2013-06-25
EP1776142B9 (en) 2016-09-07
PE20060418A1 (es) 2006-06-15
AU2005268857B8 (en) 2010-05-27
SI2364729T1 (sl) 2014-08-29
CN101001645A (zh) 2007-07-18
MX2007001338A (es) 2008-03-11
DK2364729T6 (en) 2015-07-06
DK1776142T3 (da) 2011-10-31
MY144925A (en) 2011-11-30
PT2366405E (pt) 2015-06-30
SI2366405T1 (sl) 2015-07-31
TWI359153B (en) 2012-03-01
PT1776142E (pt) 2011-10-06
RU2426741C2 (ru) 2011-08-20
NO20150065L (no) 2007-03-30
BR122018075556B1 (pt) 2022-10-18
EP1776142A1 (en) 2007-04-25
CA2573586A1 (en) 2006-02-09
WO2006013107A1 (en) 2006-02-09
CY1111963T1 (el) 2015-11-04
US20230235038A1 (en) 2023-07-27
JP2008507988A (ja) 2008-03-21
DK2902039T3 (en) 2018-07-16
PT2902039T (pt) 2018-07-17
PL1776142T4 (pl) 2018-04-30
HRP20110758T1 (en) 2011-11-30
EP2366405A3 (en) 2012-01-18
NO2015023I1 (no) 2015-11-02
LTC1776142I2 (lt) 2022-07-11
AU2010201689B2 (en) 2011-09-29
US8119131B2 (en) 2012-02-21
CN101001645B (zh) 2012-09-05
US9765140B2 (en) 2017-09-19
IL180717A0 (en) 2007-06-03
NO2018007I1 (no) 2018-02-14
NO20151787L (no) 2006-02-06
EP1776142B1 (en) 2011-07-27
HUE038187T2 (hu) 2018-10-29
AR050200A1 (es) 2006-10-04
ES2367440T9 (es) 2021-04-28
NO337286B1 (no) 2016-02-29
EP2364729B1 (en) 2014-05-14
AU2005268857B2 (en) 2010-01-28
DK2364729T3 (da) 2014-07-21
NO341384B1 (no) 2017-10-30

Similar Documents

Publication Publication Date Title
FR15C0048I2 (fr) Anticorps antagonistes de il-17
EP1964852A4 (en) ANTI-ILT7 ANTIBODY
CY2016030I1 (el) Αντισωματα εναντι της il-17
EP1765396A4 (en) ANTIBODY
NO20071430L (no) Anti-OX4OL antistoffer
EP2076614A4 (en) SYNTHETIC ANTIBODIES
EP2011869A4 (en) NEW ANTI-CD98 ANTIBODY
EP2006379A4 (en) HIGH-FUNCTIONAL BIS-SPECIFIC ANTIBODY
EP1850873A4 (en) ANTIBODIES AGAINST TGFBETA
EP1810979A4 (en) STABILIZED HUMAN IgG4 ANTIBODIES
MA29014B1 (fr) Formulations d'anticorps
EP1747756A4 (en) Lancet assembly
EP1940466A4 (en) MONOCLONAL ANTIBODY AGAINST ADDL AND USE THEREOF
EP1761566A4 (en) HUMANIZED MONOCLONAL ANTI-DAY-72 ANTIBODIES
DE602005012636D1 (de) Erung
EP2004231A4 (en) CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
DE602005017454D1 (de) Siliziumverbindung
EP1761562A4 (en) CONFORMATION SPECIFIC ANTIBODIES
EP1826218A4 (en) ANTI-HUMAN BAFF ANTIBODIES
EP1646401A4 (en) SPECIFIC HUMAN ANTIBODIES
FR2880112B1 (fr) Pese-personne
FI20041538L (fi) Goniometri
EP1712564A4 (en) MONOCLONAL ANTI-NC1 ANTIBODY
FI20041385L (fi) Symmetria-akselin määrittäminen
DE112005003066A5 (de) Geodätisches Gerät